SAN FRANCISCO and SUZHOU, China

旧金山和中国苏州

,

，

May 18, 2026

2026年5月18日

/PRNewswire/ -- Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that it will present multiple clinical and preclinical data from IBI3002(IL-4Rα/TSLP), IBI3038(IGF-1R/IL-6), IBI3031(IGF-1R/TSHR) at the 2026 American Thoracic Society (ATS) International Conference, held in Orlando, Florida (US) from May 17–20 and the 2026 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, held in Denver, Colorado (US) from May 3-7..

/PRNewswire/ -- 全球领先的生物制药公司信达生物（Innovent Biologics, Inc.，简称“Innovent”）（港交所代码：01801），致力于开发、生产和商业化用于治疗肿瘤、心血管及代谢疾病、自身免疫、眼科及其他重大疾病的高质量药物。该公司宣布，将在2026年5月17日至20日于美国佛罗里达州奥兰多举行的美国胸科学会（ATS）国际会议上，以及2026年5月3日至7日于美国科罗拉多州丹佛举行的视觉与眼科研究协会（ARVO）年会上，展示IBI3002（IL-4Rα/TSLP）、IBI3038（IGF-1R/IL-6）、IBI3031（IGF-1R/TSHR）的多项临床和临床前数据。

ATS Presentation

ATS 演示文稿

Title：

标题：

IBI3002, A First-in-class Anti-IL-4R

IBI3002，同类首创抗IL-4R

α

α

/TSLP Bispecific Antibody in Patients with Mild-To-Moderate Asthma: A Randomized, Double-Blind, Placebo-Controlled, Single Dose Phase Ib Study

在轻度至中度哮喘患者中使用TSLP双特异性抗体：一项随机、双盲、安慰剂对照、单剂量Ib期研究

Abstract Number：

摘要编号：

8579

8579

Presentation Form:

表现形式：

Poster

海报

Author：

作者：

Dr. Yuanfang Ren, Innovent Biologics

任元芳博士，信达生物

IBI3002 is a first-in-class bispecific antibody that simultaneously targets IL-4Rα and its upstream inflammatory cytokine―thymic stromal lymphopoietin (TSLP), a key cytokine involved in initiating and perpetuating the inflammatory response in the airways. In preclinical studies, IBI3002 demonstrated a significantly greater reduction in airway inflammation and immune cell infiltration compared with an anti-IL-4Rα antibody dupilumab and an anti-TSLP antibody tezepelumab.

IBI3002 是一种同类首创的双特异性抗体，可同时靶向 IL-4Rα 及其上游炎症细胞因子——胸腺基质淋巴细胞生成素 (TSLP)，这是参与启动和持续气道炎症反应的关键细胞因子。在临床前研究中，与抗 IL-4Rα 抗体度匹鲁单抗 (dupilumab) 和抗 TSLP 抗体替泽鲁单抗 (tezepelumab) 相比，IBI3002 显示出显著更强的气道炎症和免疫细胞浸润减少效果。

This Phase 1b clinical trial (NCT06213844) was initiated and has been completed in Australia. In the single-dose study, IBI3002 exhibited favorable safety and tolerability among participants with mild-to-moderate asthma, alongside improvements in multiple pharmacodynamic and pulmonary function endpoints.

这项 1b 期临床试验（NCT06213844）已在澳大利亚启动并完成。在单剂量研究中，IBI3002 在轻度至中度哮喘患者中表现出良好的安全性和耐受性，同时在多个药效学和肺功能终点方面有所改善。

Compared with placebo, the IBI3002 group achieved greater improvements in pre-bronchodilator forced expiratory volume in one second (pre-BD FEV1) (Day 36: -0.15L vs. +0.18L) and fractional exhaled nitric oxide (FeNO) (-15ppb vs. -38ppb). Meanwhile, substantial reductions were also seen in key type 2 inflammatory biomarkers: peripheral blood eosinophils (-12.5% vs.

与安慰剂相比，IBI3002组在支气管扩张剂前一秒用力呼气量（pre-BD FEV1）（第36天：-0.15L vs. +0.18L）和呼出气一氧化氮分数（FeNO）（-15ppb vs. -38ppb）方面取得了更大的改善。同时，关键的2型炎症生物标志物也显著减少：外周血嗜酸性粒细胞（-12.5% vs.

-46.53%), immunoglobulin E (IgE) levels (+8% vs. -13%), and thymus and activation-regulated chemokine (TARC) (-6% vs. -29%). These findings suggest that, under the backdrop of publicly available data on agents sharing similar mechanisms, IBI3002, with its unique IL‑4Rα/TSLP dual‑blockade mechanism, exhibits promising potential for more competitive therapeutic efficacy..

-46.53%）、免疫球蛋白 E (IgE) 水平（+8% vs. -13%）以及胸腺和活化调节趋化因子 (TARC)（-6% vs. -29%）。这些研究结果表明，在公开可获取的具有相似机制药物的数据背景下，IBI3002 凭借其独特的 IL-4Rα/TSLP 双重阻断机制，展现出更具竞争力的治疗效果潜力。

Title：Preclinical Characterization of IBI3038, An Anti-IGF-1R And Anti-IL-6 Bispecific Antibody That Potently Inhibits Lung Fibrosis Development

标题：IBI3038的临床前特性研究，这是一种有效抑制肺纤维化发展的抗IGF-1R和抗IL-6双特异性抗体

Abstract Number：

摘要编号：

14557

14557

Presentation Form:

表现形式：

Poster

海报

Author：

作者：

Dr. Yao Xiong, Innovent Biologics

姚雄博士，信达生物

IBI3038 is a first-in-class IGF-1R x IL-6 bispecific antibody currently at the Investigational New Drug (IND) enabling stage. With a unique design to simultaneously block both fibrotic and inflammatory pathways, it aims at addressing large and urgent unmet needs in fibrosis-related autoimmune diseases，including scleroderma related interstitial lung disease (SS-ILD).

IBI3038 是一款首创的 IGF-1R x IL-6 双特异性抗体，目前处于新药临床试验（IND）启用阶段。凭借独特设计同时阻断纤维化和炎症通路，它旨在满足纤维化相关自身免疫疾病中巨大且迫切的未满足需求，包括硬皮病相关间质性肺病（SS-ILD）。

In preclinical studies，IBI3038 potently and synergistically inhibited IGF-1 and cis- as well as trans- IL-6 signaling superior to Teprotumumab. It robustly suppressed HA production by and proliferation of human lung and dermal fibroblasts. Besides, IBI3038 significantly inhibited collapse of alveoli (atelectasis) and collagen deposits on human iPSC induced lung organoids, better than IL-6 mAb.

在临床前研究中，IBI3038 强效且协同地抑制了 IGF-1 和顺式及反式 IL-6 信号传导，效果优于 Teprotumumab。它显著抑制了人肺和皮肤成纤维细胞的透明质酸生成和增殖。此外，IBI3038 在人 iPSC 诱导的肺类器官中显著抑制了肺泡塌陷（肺不张）和胶原沉积，效果优于 IL-6 单克隆抗体。

Lastly, in a mouse model, dual blockade of IL-6 and IGF-1R significantly suppressed lung fibrosis development and skin thickening, while no such effect was observed with either IGF-1R or IL-6 mAb treatment. To summarize, IBI3038 will provide new treatment options to SS-ILD patients by synergistically blocking the keys factors in both fibrotic and inflammatory pathways..

最后，在小鼠模型中，同时阻断IL-6和IGF-1R显著抑制了肺纤维化的发展和皮肤增厚，而单独使用IGF-1R或IL-6单克隆抗体治疗则未观察到此类效果。总之，IBI3038通过协同阻断纤维化和炎症通路中的关键因素，将为SS-ILD患者提供新的治疗选择。

ARVO Presentation

ARVO 演示文稿

Title: IBI3031 an anti-IGF-1R/TSHR bispecific antibody shows potential therapeutic benefit in preclinical study

标题：IBI3031，一种抗IGF-1R/TSHR双特异性抗体，在临床前研究中显示出潜在的治疗益处

Abstract Number:

摘要编号：

1154 - 0884

1154 - 0884

Presentation Form:

表现形式：

Poster

海报

Author:

作者：

Dr. Yiming Li, Innovent Biologics

李一鸣博士，信达生物

IBI3031 is a pioneering bispecific antibody designed to target both the Insulin-like Growth Factor-1 Receptor (IGF-1R) and the Thyroid-Stimulating Hormone Receptor (TSHR). By leveraging dual-target synergy and advanced antibody engineering, IBI3031 aims to surpass current Standard of Care (SoC) efficacy while optimizing delivery routes for future clinical use.

IBI3031 是一种首创的双特异性抗体，旨在靶向胰岛素样生长因子 1 受体 (IGF-1R) 和促甲状腺激素受体 (TSHR)。通过利用双靶点协同作用和先进的抗体工程技术，IBI3031 力求超越当前的标准治疗 (SoC) 疗效，同时优化未来临床使用的递送途径。

By neutralizing both IGF-1R and TSHR simultaneously, IBI3031 significantly inhibited the proliferation, hyaluronic acid secretion, and myofibroblast differentiation of orbital fibroblasts derived from patients with Thyroid Eye Disease (TED) and attenuates the hyperactivation of thyroid cells. In murine TED models, the molecule effectively suppressed the expansion of orbital adipose and muscular tissues.

通过同时中和IGF-1R和TSHR，IBI3031显著抑制了来自甲状腺眼病（TED）患者的眶成纤维细胞的增殖、透明质酸分泌和肌成纤维细胞分化，并减弱了甲状腺细胞的过度激活。在小鼠TED模型中，该分子有效抑制了眶脂肪和肌肉组织的扩张。

In Pharmacokinetics & Pharmacodynamics (PK/PD) Studies in Non-Human Primates (NHPs), IBI3031 demonstrated a superior PK profile compared to existing SoCs. These results suggest a potential for extended dosing intervals, which will markedly reduce the treatment burden for patients. With its dual-pathway inhibition and optimized molecular profile, IBI3031 stands as a promising candidate for the next generation of TED therapies, offering the possibility of enhanced clinical outcomes and more convenient administration protocols.

在非人灵长类动物（NHP）的药代动力学和药效学（PK/PD）研究中，IBI3031表现出优于现有标准治疗（SoC）的药代动力学特性。这些结果表明有望延长给药间隔，从而显著减轻患者的治疗负担。凭借其双通路抑制和优化的分子特性，IBI3031成为下一代TED疗法的有前景候选者，可提供提升临床疗效和更便捷给药方案的可能性。

Dr. Lei Qian, Chief R&D Officer (General Biomedicine) of Innovent Biologics,

雷谦博士，信达生物制药（研发）首席官（普通生物医药），

stated：'At the 2026 ATS and ARVO Annual Meetings, we showcased our next-generation bispecific antibodies for autoimmune and ophthalmological diseases. Our first-in-class anti-IL-4Rα/TSLP bispecific antibody, IBI3002, simultaneously targets key type 2 inflammation pathways. It has the potential to deliver more comprehensive and sustained solution for patients with highly heterogeneous asthma, thereby addressing critical unmet needs, particularly suboptimal disease control.

表示：“在2026年ATS和ARVO年会上，我们展示了用于自身免疫和眼科疾病的下一代双特异性抗体。我们的首创抗IL-4Rα/TSLP双特异性抗体IBI3002，同时靶向关键的2型炎症通路。它有潜力为高度异质性哮喘患者提供更全面且持久的解决方案，从而满足尚未满足的关键需求，特别是疾病控制不佳的问题。”

The phase Ib data showed IBI3002 significantly improved lung function and other indicators with good tolerability. We will advance its development for asthma and atopic dermatitis. IBI3038 and IBI3031 will also enter clinical stages in 2026. We remain committed to addressing unmet global clinical needs by advancing mechanism-driven innovation and pipeline development.'.

Ib期数据显示，IBI3002显著改善了肺功能和其他指标，且具有良好耐受性。我们将推进其在哮喘和特应性皮炎方面的开发。IBI3038和IBI3031也将在2026年进入临床阶段。我们始终致力于通过推动机制驱动的创新和管线开发来满足全球未被满足的临床需求。

Dr. Huizhong Xiong, Vice President of Innovent Academy (Preclinical R&D of General Biomedicine) of Innovent Biologics,

熊慧中博士，信达生物制药集团信达学院（通用生物医药临床前研发）副院长，

stated: 'The preclinical programs presented at these conferences further validate our R&D capabilities in bispecific platforms and mechanism innovation. Specifically, we explore paths to breaking the cross-talk and amplification loop of fibrosis, inflammation and metabolic abnormality. These achievements reflect the company's in-depth exploration of key pathogenic mechanisms.

表示：“这些会议上展示的临床前项目进一步验证了我们在双特异性平台和机制创新方面的研发能力。具体来说，我们探索了打破纤维化、炎症和代谢异常之间的串扰和放大循环的路径。这些成果反映了公司对关键致病机制的深入探索。”

In the future, we will continue to rely on our proprietary innovation platforms to advance the R&D of next-generation bispecific antibodies with global competitiveness, providing patients with more differentiated treatment options.'.

未来，我们将继续依托自主研发创新平台，推进具有全球竞争力的下一代双特异性抗体药物的研发，为患者提供更具差异化的治疗选择。"

About Innovent

关于信达

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases.

信达生物是一家领先的生物制药公司，成立于2011年，其使命是为全球患者提供负担得起的高质量生物制药。公司致力于发现、开发、生产和商业化针对一些最棘手疾病的创新药物。其开创性疗法用于治疗癌症、心血管和代谢疾病、自身免疫性疾病以及眼科疾病。

Innovent has launched 18 products in the market. It has 5 assets in Phase III or pivotal clinical trials and 14 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center..

信达生物已将18款产品推向市场，另有5款资产处于III期或关键性临床试验阶段，14款分子处于早期临床阶段。信达生物与30多家全球医疗保健公司建立了合作伙伴关系，包括礼来、罗氏、武田、赛诺菲、Incyte、LG化学和MD安德森癌症中心。

Guided by the motto, 'Start with Integrity, Succeed through Action,' Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit

信达秉持“始于信，达于行”的理念，致力于维护最高标准的行业规范，携手推进生物制药行业的发展，使一流的药物能够广泛普及。欲了解更多信息，请访问

www.innoventbio.com

www.innoventbio.com

, or follow Innovent on Facebook and LinkedIn.

，或者在Facebook和LinkedIn上关注信达。

Forward-looking statement

前瞻性声明

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words 'anticipate', 'believe', 'estimate', 'expect', 'intend' and similar expressions, as they relate to Innovent Biologics ('Innovent'), are intended to identify certain of such forward-looking statements.

本新闻稿可能包含某些前瞻性陈述，这些陈述因其性质而受到重大风险和不确定性的影响。与信达生物制药（“信达”）相关的“预期”、“相信”、“估计”、“预计”、“意图”及类似表述旨在识别其中某些前瞻性陈述。

The Company does not intend to update these forward-looking statements regularly..

公司不打算定期更新这些前瞻性声明。

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict.

这些前瞻性声明是基于公司管理层在作出这些声明时对未来事件的现有信念、假设、期望、估计、预测和理解。这些声明并非对未来发展的保证，并且受到风险、不确定性和其他因素的影响，其中一些因素是公司无法控制的，并且难以预测。

Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions..

因此，由于我们业务、公司竞争环境以及政治、经济、法律和社会状况的未来变化或发展，实际结果可能与前瞻性陈述中包含的信息有重大差异。

The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.

公司、董事及公司员工：(a) 没有义务更正或更新本网站所含前瞻性陈述；(b) 在任何前瞻性陈述未实现或不正确的情况下不承担责任。

SOURCE Innovent Biologics

来源：信达生物

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示